ArticleFrontiers in cardiovascular medicine2025
Bibliometric and visual analysis of miRNAs in heart diseases from 2004 to 2023.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRNAs) add a new dimension to HD forecast, diagnosis, and therapy based on the potential applications. The miRNA-related research in the heart disease (HD) field has received close attention in the past two decades. However, there is a lack of studies that comprehensively and objectively analyze the current situation of miRNA application in the HD field using the bibliometrics method. Objective: To comprehensively analyze the global scientific outputs of miRNAs in HD research from 2004 to 2023. Methods: All the articles and reviews of miRNA-related research in the HD field were retrieved using the Web of Science core collection (WOSCC) title search, and bibliometric analysis was performed in Microsoft Excel 2019, CiteSpace, VOSviewer, and Bibliometrics (R-Tool of R-Studio). Results: 3,874 publications were included in the bibliometric analysis. Collaborative network analysis indicates that China with the maximum number of publications (2,063) and the USA with the highest total citations (59,331) are influential countries in this field. Peking Union Medical College is the most prolific university with the maximum publications (134), and the University of California System is the most authoritative institution regarding betweenness centrality (0.27). PLOS ONE tops the journal list of publications, closely followed by the International Journal of Molecular Sciences and Scientific Reports with more than 100 articles. Considering the number of publications, citations, and total link strength overall, Olson. Eric N, Van Rooij Eva, Thum Thomas, Yang Baofeng, Wang Kun; and Lu Yanjie are authoritative authors in this field. The expression changes and regulatory mechanisms of specific miRNAs in various heart biological and pathophysiological processes have been the continuous research hotspots. "exosomes", "extracellular vesicles", "autophagy", and "management" have been novel hot research topics since 2018, which focused on the diagnosis and treatment of HD. The current research development trend is how to translate the achievement of miRNA-related diagnosis and therapeutic drugs for HD into the clinic. Conclusion: Our study revealed the intellectual structure of miRNA in HD research, which may help scholars understand this field comprehensively and find partners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.